We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal appeals court has upheld Mylan’s challenge to a Biogen patent covering the latter’s blockbuster multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate). Read More
The new center is located near two large hospitals and a life sciences cluster that, with 400 companies, is the largest in Europe, AstraZeneca said. Read More
GlaxoSmithKline (GSK) has forged an exclusive license agreement with Arrowhead Pharmaceuticals to develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic currently in a phase 1/2 trial. The deal is potentially worth more than $1 billion. Read More
Arcus is now “well-positioned to accelerate and expand clinical development activities … [for] patients with some of the most difficult to treat cancers, including pancreatic, lung, colon and prostate,” said Arcus CEO Terry Rosen. Read More
Novo Nordisk plans to acquire Dicerna Pharmaceuticals for $3.3 billion, a move that will net Novo Nordisk a ribonucleic acid interference (RNAi) platform for identifying genes that can be targeted to develop drug candidates across many therapeutic areas. Read More
Humira’s increased U.S. price “contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,” noted David Rind, ICER’s chief medical officer. Read More
AbbVie’s rheumatoid arthritis drug Humira (adalimumab) and six other drugs whose prices were raised in 2020 without supportive clinical data cost the U.S. health system $1.67 billion in annual drug spending, according to a new analysis released yesterday by the Institute for Clinical and Economic Review (ICER). Read More
The “new” J&J aims to strengthen its pharmaceuticals and medical devices portfolio, which is projected to rake in $77 billion in 2021 revenue. Read More
The Federal Trade Commission (FTC) has approved certain modifications to Bristol Meyers Squibb’s (BMS) divestiture agreements as part of the company’s 2019 acquisition of Celgene. Read More